Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Stablizing an enzyme by forming a mixture – an adduct or a...
Reexamination Certificate
1998-10-30
2003-11-18
Prats, Francisco (Department: 1651)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Stablizing an enzyme by forming a mixture, an adduct or a...
C530S383000, C530S380000, C530S381000, C530S384000, C514S053000, C514S777000, C435S002000
Reexamination Certificate
active
06649386
ABSTRACT:
This invention relates to dried compositions of blood factors for reconstitution with water or aqueous solutions.
Blood factors, particularly factor VIII and factor IX, are now the standard treatment for diseases caused by a lack of the appropriate factor, in particular haemophilia. The blood factor has generally been derived from human blood by various extraction techniques, for example as disclosed in EP-A-0083483, or by expression in genetically modified micro-organisms, for example as disclosed in EP-A-0160457 and EP-A-0182448.
Blood factor products such as factor VIII are highly delicate, unstable proteins. They are usually supplied in the form of frozen solutions in an appropriate buffer or, more generally, as freeze-dried powders. Even the freeze-dried powders must be kept cold during storage. In order to stabilise the freeze-dried material, commercial products contain a stabilising protein, in particular human serum albumin (HSA). It has not been thought possible to prepare a dry blood factor composition which is stable at ambient temperatures and at pasteurisation temperatures (e.g. 60° C.) in the absence of HSA. However, the presence of HSA introduces considerable problems of purification since it is essential that the protein is free of viral contamination. The use of recombinant HSA to overcome these problems is expensive.
Trehalose is known to be a highly effective stabilising agent for delicate proteins, as disclosed in U.S. Pat. No. 4,891,319, enabling proteins to be dried at temperatures above freezing. We have now found that if trehalose is used to stabilise a blood factor product, not only can the product be dried with or without freezing, but also the product is stable even when retained at a temperature of 60° C. for an extended period, in the complete absence of HSA. According to the present invention therefore we provide a stable dried blood factor composition containing a stabilising amount of trehalose in the absence of albumin.
In general, any stabilising amount of trehalose may be used and an excess in general causes no problems. Indeed, the presence of trehalose aids the rehydration process and is physiologically acceptable for injection, being rapidly metabolised to glucose. In general a ratio of about 0.2 mg to 2.5 mg trehalose per unit of factor VIII is desirable, especially 0.2 to 1.5 mg/unit. The composition is particularly suited to formulations of factor VIII, which may also contain appropriate buffering and ion-reinforcing salts, in particular a source of calcium. In general, a ratio of about 1.0 to 1.5 &mgr;g of calcium ions per unit of factor VIII is appropriate.
Other buffering and modifying agents may also be present in the dried material for reconstitution to the injection solution, for example histidine. However, we have found that the level of salts, particularly sodium chloride, present can affect the preservation on drying. It is thought desirable for the commercial product for injection to have an isotonic salt concentration. However, the processing formulations which are freeze-dried are desirably hypertonic, typically containing about 500 mM NaCl (isotonic NaCl =150 mM), as this is considered to help stabilise the blood factor. As a result, commercial freeze-dried formulations generally have a high salt content and are reconstituted for injection with the appropriate amount of sterile water to obtain an isotonic solution.
A considerably reduced salt content is preferred for the dried material of the invention and, in general a solution of about 500 units of Factor VIII per ml to be dried should preferably contain less than 200 mM e.g. 75 to 150 mM, NaCl, especially about 100 mM., but can be even lower, e.g. 20 to 50 mM, especially about 22 to 30 mM. Low salt preparations possess a higher dry stability. The dried product can be reconstituted to the desired salt level with a saline solution instead of the conventional water. In general, the molar ratio of trehalose to salt should be above 1:1, especially above 2.5:1 e.g. above 10:1, preferably above 12.5:1.
The dried composition may be obtained by drying an appropriate solution of the blood factor containing the correct proportions of trehalose and other desired components. In general, the solution that is dried should simply contain all the components required in the reconstituted injection solution, although the solution for drying may not necessarily be at the same dilution. Typically, the solution for drying will contain from 1 to 1000 units of factor VRI per ml. The methods of drying may include freeze drying, vacuum drying and spray-drying. A particularly preferred method according to the invention comprises vacuum drying at a temperature no greater than 25° C., preferably no greater than 10° C., to form a foam, thus maximising the exposed surface and the drying effect.
The following examples illustrate the invention further.
REFERENCES:
patent: 4495175 (1985-01-01), Chavin et al.
patent: 4758657 (1988-07-01), Farb et al.
patent: 4806343 (1989-02-01), Carpenter et al.
patent: 4891319 (1990-01-01), Roser
patent: 5364756 (1994-11-01), Livesey et al.
patent: 5576291 (1996-11-01), Curtis et al.
patent: 0 314 095 (1989-05-01), None
patent: 0 475 409 (1992-03-01), None
patent: WO 87/00196 (1987-01-01), None
patent: WO 94/07510 (1994-04-01), None
patent: WO 95/01804 (1995-01-01), None
patent: WO 95/07713 (1995-03-01), None
Roser, B., et al., “Trehalose Drying: A Novel Replacement for Freeze-Drying,”BioPharm(1991) 4(8):47-53.
Cleland, J.L., et al. (ed.), “Design and Development Strategies,” Chapter 1 in Formulation and Delivery of Proteins and Peptides,American Chemical SocietySymposium Series 567 (1994):1-19.
Prats Francisco
Quadrant Drug Delivery Limited
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Dried blood factor composition comprising trehalose does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dried blood factor composition comprising trehalose, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dried blood factor composition comprising trehalose will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3167995